共 11 条
[11]
Treatment Guidelines Panel, 2023, COR DIS 2019 COVID 1
No effects of nirmatrelvir/ritonavir on darunavir plasma trough concentrations: a case report
被引：0
作者：
Cattaneo, Dario
[1
]
Pagano, Simone
[1
]
Lazzarin, Samuel
[1
]
Calvagna, Nunziata
[1
]
Gervasoni, Cristina
[1
]
机构：
[1] ASST Fatebenefratelli Sacco, I-20157 Milan, Italy
关键词：
COMMUNICABLE DISEASES;
COVID-19;
DRUG INCOMPATIBILITY;
Case Reports;
Clinical Competence;
Drug Monitoring;
EFFICACY;
SAFETY;
D O I：
10.1136/ejhpharm-2023-004015
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
COVID-19 may be associated with worst outcomes in people living with HIV compared with HIV-negative patients. Nirmatrelvir/ritonavir can be safely co-administered with all the HIV antiretroviral drugs, without considering dose adjustment. However, no studies have formally investigated the effect of a double booster (ritonavir plus cobicistat) regimen on darunavir concentrations. We presented a case describing the lack of effects of adding nirmatrelvir/ritonavir on darunavir plasma trough concentrations in a patient with HIV already on treatment with a booster-based antiretroviral regimen. We believe this could be a reassuring message for physicians, allowing them to prevent unnecessary denial of COVID-19 treatment or inappropriate discontinuation of co-medications in patients with HIV.
引用
收藏
页码：87 / 88
页数：2
相关论文